Robert H. Zimmer

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

J. Gómez-Reino, S. Muller, H. Scherbarth, 2012, Annals of the rheumatic diseases.

Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo

G. Guichard, L. Mauran, Juliette Fremaux, 2019, Nature Communications.

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.

S. Muller, F. Monneaux, J. Geiger, 2008, Arthritis and rheumatism.

Spliceosomal Peptide P 140 for Immunotherapy of Systemic Lupus Erythematosus Results of an Early Phase II Clinical Trial

S. Muller, F. Monneaux, J. Geiger, 2008 .

Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02079a

D. Rognan, G. Guichard, B. Jones, 2019, Chemical science.